

ARTICLE

Received 20 Aug 2014 | Accepted 5 Jun 2015 | Published 17 Jul 2015

DOI: 10.1038/ncomms8737

OPEN

# Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia

June Li<sup>1,2,3,\*</sup>, Dianne E. van der Wal<sup>2,3,4,\*</sup>, Guangheng Zhu<sup>2,3,\*</sup>, Miao Xu<sup>1,2,3</sup>, Issaka Yougbare<sup>2,3,4</sup>, Li Ma<sup>2,3,4</sup>, Brian Vadasz<sup>1,2,3</sup>, Naadiya Carrim<sup>2,3</sup>, Renata Grozovsky<sup>5</sup>, Min Ruan<sup>6</sup>, Lingyan Zhu<sup>6</sup>, Qingshu Zeng<sup>6</sup>, Lili Tao<sup>6</sup>, Zhi-min Zhai<sup>6</sup>, Jun Peng<sup>7</sup>, Ming Hou<sup>7</sup>, Valery Leytin<sup>1,2,3</sup>, John Freedman<sup>1,2,3,8</sup>, Karin M. Hoffmeister<sup>5</sup> & Heyu Ni<sup>1,2,3,4,8,9</sup>

Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by autoantibodies against platelet GPIIb/IIIa and/or the GPIb complex. Current theory suggests that antibody-mediated platelet destruction occurs in the spleen, via macrophages through Fc-Fc $\gamma$ R interactions. However, we and others have demonstrated that anti-GPIb $\alpha$  (but not GPIIb/IIIa)-mediated ITP is often refractory to therapies targeting Fc $\gamma$ R pathways. Here, we generate mouse anti-mouse monoclonal antibodies (mAbs) that recognize GPIb $\alpha$  and GPIIb/IIIa of different species. Utilizing these unique mAbs and human ITP plasma, we find that anti-GPIb $\alpha$ , but not anti-GPIIb/IIIa antibodies, induces Fc-independent platelet activation, sialidase neuraminidase-1 translocation and desialylation. This leads to platelet clearance in the liver via hepatocyte Ashwell–Morell receptors, which is fundamentally different from the classical Fc-Fc $\gamma$ R-dependent macrophage phagocytosis. Importantly, sialidase inhibitors ameliorate anti-GPIb $\alpha$ -mediated thrombocytopenia in mice. These findings shed light on Fc-independent cytopenias, designating desialylation as a potential diagnostic biomarker and therapeutic target in the treatment of refractory ITP.

<sup>1</sup>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8. <sup>2</sup>Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8. <sup>3</sup>Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8. <sup>4</sup>Canadian Blood Services, Ottawa, Ontario, Canada K1G 4J5. <sup>5</sup>Translational Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. <sup>6</sup>Department of Hematology, Anhui Medical University, Hefei 230032, China. <sup>7</sup>Department of Hematology, Qilu Hospital, Shandong University, Jinan 250012, China. <sup>8</sup>Department of Medicine, University of Toronto, Ontario, Canada M5S 1A8. <sup>9</sup>Department of Physiology, University of Toronto, Ontario, Canada M5S 1A8. \* These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.N. (email: nih@smh.ca).

Immune thrombocytopenia (ITP) is a common bleeding disorder characterized by increased destruction of autologous platelets<sup>1–3</sup>. Low platelet counts increase the risk for bleeding, which leads to severe intracranial haemorrhage in ~5% of patients<sup>1–3</sup>. ITP patients live with the risk of fatal bleeding and many undergo long-term therapeutic regimens to manage platelet counts, and suffer a marked decrease in quality of life<sup>4</sup>. First-line treatments include immunosuppressive and immunomodulatory agents (that is, corticosteroids, intravenous immunoglobulin G (IVIG) and anti-RhD therapy). Splenectomy has to be considered for patients with a persistent lack of response to treatment<sup>5</sup>. However, it is estimated that 15–25% of patients are inexplicably refractory to first-line therapies and even splenectomy<sup>6</sup>. To date, there is no reliable measurement in the clinical setting to predict the success or failure of any ITP treatment<sup>5,7</sup>.

Autoantibodies targeting platelet surface glycoprotein(s) (GP) have been demonstrated to be the major factors responsible for platelet clearance<sup>2,8,9</sup>. Approximately 70–80% of patients have autoantibodies against GPIIb/IIIa (integrin  $\alpha$ IIB $\beta$ 3), 20–40% against the GPIb complex and some patients have autoantibodies against both or other GPs<sup>11–13</sup>. Platelet destruction following autoantibody binding has generally been considered to occur in the spleen, through binding of the Fc portion of immunoglobulins on the platelet surface to Fc $\gamma$ RIIa and Fc $\gamma$ RIIIa on tissue macrophages of the reticuloendothelial system<sup>2</sup>. Accordingly, first-line therapies, such as IVIG and anti-Rh(D), target these Fc- and Fc $\gamma$ R-dependent mechanisms to restore platelet numbers<sup>10</sup>. Unexpectedly, we and others have identified a novel mechanism of Fc-independent thrombocytopenia, in which antibodies against GPIb $\alpha$ , but not those against GPIIb/IIIa, can induce thrombocytopenia via their F(ab)<sub>2</sub> (Fc independent) and in Fc $\gamma$ R<sup>-/-</sup> mice<sup>11,12</sup>. We further reported that most anti-GPIb $\alpha$  antibody-mediated thrombocytopenia is resistant to IVIG treatment<sup>12</sup>. This is consistent with subsequent reports in humans, including our recent large patient cohort study<sup>13–15</sup>. In addition, our retrospective studies suggest that ITP patients with anti-GPIb $\alpha$  antibodies are also more likely to be refractory to steroid treatments<sup>16</sup>. These data indicate that anti-GPIb $\alpha$  antibodies are able to uniquely induce platelet clearance in an Fc-independent manner in murine models, which may also be true in human ITP. However, the nature of this novel Fc-independent mechanism of platelet clearance is unknown.

GPIIb/IIIa and the GPIb complex are structurally and functionally distinct platelet receptors. Although different outside-in signalling pathways have been observed between these two receptors following ligand stimulation<sup>17,18</sup>, the downstream effects of autoantibody binding have not been adequately studied. Thus, possible differences in pathogenesis and therapy between anti-GPIIb/IIIa- and anti-GPIb-mediated ITP remain to be elucidated.

As the second-most abundant platelet surface receptor, GPIb $\alpha$  is the largest subunit and possesses all known extracellular ligand-binding sites of the GPIb complex (that is, GPIb-IX-V). Binding of GPIb $\alpha$  to the von Willebrand factor initiates GPIb $\alpha$  outside-in signalling, which can subsequently activate GPIIb/IIIa leading to platelet aggregation<sup>17,19</sup>. GPIb $\alpha$  is also the most heavily glycosylated platelet surface protein with ~60% carbohydrate by weight<sup>20</sup>. It contains both N- and O-linked carbohydrate chains capped with sialic acid, contributing to 64% of the total sialic acid content of the platelet<sup>21</sup>. Deglycosylation of GPIb $\alpha$  was reported to result in hepatic clearance of cold-stored platelets following transfusion<sup>22–24</sup>. This suggests that glycan modification of GPIb $\alpha$  may be sufficient to induce platelet clearance, likely via an Fc-independent pathway. We previously found that antisera against GPIb $\alpha$  can induce platelet activation<sup>25</sup>; however, other downstream platelet responses following antibody binding have

not been adequately studied. Whether antibody binding may also lead to deglycosylation and contribute to platelet clearance, and whether this may account for the differences in pathogenesis and response to therapy in ITP has not been investigated.

In this study, by utilizing unique anti-GPIb $\alpha$  and anti-GPIIb/IIIa monoclonal antibodies (mAbs) as well as human ITP plasma samples, we show that significant platelet activation and desialylation occurs predominantly in the presence of anti-GPIb $\alpha$ , but not anti-GPIIb/IIIa antibodies *in vitro* and *in vivo*. Furthermore, anti-GPIb $\alpha$ -mediated desialylation of platelets led to Fc $\gamma$ R-independent clearance via hepatocytes. Most importantly, the use of sialidase inhibitors mitigated thrombocytopenia in a murine model of anti-GPIb $\alpha$ -mediated ITP. Thus, we identify a mechanism of platelet clearance previously undescribed. In addition, we introduce a new diagnostic method to detect platelet desialylation in ITP and establish sialidase inhibitors as a potential therapeutic for refractory ITP.

## Results

### Generation of novel anti-GPIb $\alpha$ and anti-GPIIb/IIIa antibodies.

To examine the effects of anti-GPIb $\alpha$  and anti-GPIIb/IIIa antibodies on platelet function and clearance, we utilized gene-deficient (<sup>-/-</sup>) mice to generate a panel of mouse anti-mouse-GPIb $\alpha$  and -GPIIb/IIIa mAbs, which possess cross-reactivity against other species, including tested human, rat and/or pig antigens (Table 1). These are the first syngeneic anti-GPIb $\alpha$  antibodies utilized in the study of ITP, thus circumventing xenogeneic antibody complications. To our knowledge, this is also the first report that anti-GPIb $\alpha$  antibodies can cross-react with GPIb $\alpha$  from different species. Further characterization of these antibodies revealed that some of these mAbs affect ristocetin/botrocetin- or ADP/thrombin-induced platelet aggregation, which are mediated by GPIb $\alpha$ <sup>26</sup> or GPIIb/IIIa, respectively (Table 1)<sup>27–29</sup>. Injection of these antibodies into mice induced significant platelet decrease (thrombocytopenia) with no significant effects on red or white blood cell counts (Supplementary Table 1). Thus, these mAbs may serve useful in the study of different animal models of human diseases, including thrombosis and hemostasis, as well as other immune-mediated thrombocytopenias.

### Anti-GPIb $\alpha$ antibodies induce significant platelet activation.

It has been previously reported that antibodies against GPIb $\alpha$  may induce platelet activation<sup>25,30,31</sup>. Therefore, we investigated whether our newly developed anti-GPIb $\alpha$  mAbs may also affect platelet function. We incubated murine and human platelets with various anti-GPIb $\alpha$  or anti-GPIIb/IIIa mAbs of different immunoglobulin (Ig)G subclasses (Table 1). Three anti-GPIb $\alpha$  mAbs (NIT B, NIT C and NIT F) were employed in our human platelet studies as they were, to the best of our knowledge, the first and only currently available mAbs that are cross-reactive to human GPIb $\alpha$ .

Platelet granule secretion (surface expression of P-selectin) was significantly increased in the presence of all anti-GPIb $\alpha$  mAbs tested in both mouse and human platelets (Fig. 1a,e). To circumvent biases stemming from the specific binding epitopes of individual antibody clones, we also tested polyclonal sera against GPIb $\alpha$  and GPIIb/IIIa (generated in knockout mice immunized with wild-type (WT) platelets<sup>25</sup>). Similarly, we found anti-GPIb $\alpha$ , but not anti-GPIIb/IIIa, sera induced platelet P-selectin expression dose dependently (Fig. 1b). Consistent with P-selectin expression, we detected significantly increased platelet GPIIb/IIIa activation following anti-GPIb $\alpha$  treatment, as measured by JON/A (Fig. 1c,d) and PAC-1 binding (Fig. 1f). JON/A and PAC-1 are specific mAbs against murine and human

GPIIbIIIa, respectively, that bind exclusively to the cation-dependent high-affinity conformation of GPIIbIIIa<sup>32,33</sup>. Anti-GPIIbIIIa-induced platelet aggregation was also visualized by light microscopy (Supplementary Fig. 1). None of the anti-GPIIbIIIa antibodies tested induced detectable increases in murine platelet P-selectin expression (Fig. 1a,b). However, some anti-GPIIbIIIa antibodies, in particular mAb clone 9D2, did induce significant P-selectin expression on human platelets of certain (3 of the 10) healthy donors (Fig. 1e). We suspected this may have been due to immune-complex binding of FcγRIIa expressed exclusively on human but not murine platelets<sup>34</sup>, which has been previously shown to cause platelet granule release independent of additional agonists<sup>35</sup>. To test this possibility, we utilized the FcγRIIa/III blocker IV.3, and found that it completely attenuated 9D2-mediated P-selectin expression. Interestingly, IV.3 did not have any significant effect on any anti-GPIIbIIIa mAb-mediated human platelet activation (Fig. 1g).

Finally, utilizing plasma samples obtained from a cohort of ITP patients, we found anti-GPIIbIIIa ITP plasma induced significant P-selectin expression, while anti-GPIIbIIIa ITP plasma induced only moderate P-selectin expression (Fig. 1h). These experiments demonstrate that antibodies against GPIIbIIIa induced higher platelet activation, while anti-GPIIbIIIa antibodies may induce platelet activation in some human platelets through an FcγRIIa-dependent mechanism (Fig. 1g). These differences between anti-GPIIbIIIa and anti-GPIIbIIIa antibody-induced platelet activation may serve as the basis for the mechanistic differences between anti-GPIIbIIIa Fc-dependent and anti-GPIIbIIIa Fc-independent platelet clearance.

**Anti-GPIIbIIIa antibodies induce platelet desialylation.** Antibody-mediated platelet desialylation has not been previously investigated. To test whether anti-GPIIbIIIa antibodies also induce platelet desialylation, we quantified the binding of fluorescein-conjugated *Ricinus communis* agglutinin I (RCA-1) lectins, which specifically target exposed galactose residues following GP desialylation<sup>23,36</sup>. We found that all anti-GPIIbIIIa mAb-treated platelets (both murine and human) exhibited significant desialylation (Fig. 2a,e). This desialylation was dose dependent, with increasing concentrations of both our mAb (Fig. 2b,f) and GPIIbIIIa antisera (Fig. 2c). Platelet glycosylation changes were further characterized with additional lectins including peanut agglutinin (PNA), Sambucus Nigra Lectin and Maackia Amurensis Lectin II.

Although only significantly increased binding of PNA was observed on murine platelets, increased binding of all the lectins to human platelets occurred following anti-GPIIbIIIa mAbs incubations (Supplementary Fig. 2). To confirm that desialylation is a direct consequence of antibody binding, we measured anti-GPIIbIIIa-mediated desialylation in the presence of 2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid (DANA), a synthetic mammalian and bacterial/viral pan-sialidase inhibitor, which possesses a reported half-maximal inhibitory concentration of ~80 μM against mammalian neuraminidase-1 (NEU1)<sup>37</sup>. DANA was found to significantly decrease anti-GPIIbIIIa-mediated desialylation of murine and human platelets (Fig. 2d,g). In addition, DANA had no effect on desialylation of GPIIbIIIa<sup>-/-</sup> platelets treated with anti-GPIIbIIIa mAbs (Supplementary Fig. 3).

In contrast, although anti-GPIIbIIIa mAbs did not significantly affect desialylation on murine platelets, clones 9D2, M1 and HUTA B did cause desialylation on platelets from certain individual donors (Fig. 2e). Similar to what was observed in platelet activation, desialylation caused by anti-GPIIbIIIa mAbs (9D2, M1 and HUTA B) was FcγRIIa dependent, as blocking with IV.3 completely attenuated the response (Fig. 2h). Importantly, when healthy human platelets were incubated with plasma from ITP patients, anti-GPIIbIIIa ITP plasma triggered significant RCA-1 binding, while anti-GPIIbIIIa ITP plasma-induced RCA-1 binding was moderate (Fig. 2i).

Together these results confirm that increased sialidase activity resulting in desialylation directly follows from anti-GPIIbIIIa antibody binding. Thus, platelet desialylation may be an important biomarker for platelet activation and for anti-GPIIbIIIa-mediated ITP.


**The GPIIbIIIa subunit is predominantly desialylated.** Given that GPIIbIIIa is the most heavily glycosylated subunit on the platelet surface<sup>38</sup>, we suspected that GPIIbIIIa may be the principle target of desialylation. To test this, we utilized *O*-sialoglycoprotein endopeptidase (OSGE) to selectively remove the extracellular N terminus of GPIIbIIIa<sup>39</sup>. Evaluation of RCA-1 binding before and after OSGE treatment revealed that binding decreased to almost baseline levels following removal of GPIIbIIIa (Fig. 2j). In addition, following anti-GPIIbIIIa mAb treatment, platelet lysate was blotted with RCA-1 and a commercial anti-GPIIbIIIa antibody that identified a polypeptide corresponding to around 150 kDa. Western blotting confirmed RCA-1 binding was strongest on

**Table 1 | Characterization of mouse anti-mouse mAb against GPIIbIIIa and GPIIIa.**

Clone name	IgG subtype	Antigen	Species cross-reactivity (tested)	Inhibits murine platelet aggregation	Inhibits human platelet aggregation
<b>NIT A</b>	<b>IgG 2a</b>	<b>GPIIbIIIa</b>	<b>h, m, p</b>	<b>Yes</b>	<b>Yes</b>
<b>NIT B</b>	<b>IgG 2a</b>	<b>GPIIbIIIa</b>	<b>h, m, p</b>	<b>Yes</b>	<b>Yes</b>
<b>NIT F</b>	<b>IgG 2a</b>	<b>GPIIbIIIa</b>	<b>h, m, p</b>	<b>Yes</b>	<b>Yes</b>
NIT E	IgG 2b	GPIIbIIIa	m	Yes	NA
NIT G	IgG 1	GPIIbIIIa	m	Yes	NA
NIT H	IgG 1	GPIIbIIIa	m	Yes	NA
<b>9D2</b>	<b>IgG 1</b>	<b>GPIIbIIIa</b>	<b>h, m, p, r</b>	<b>Yes</b>	<b>No</b>
<b>M1</b>	<b>IgG 1</b>	<b>GPIIbIIIa</b>	<b>h, m, p, r</b>	<b>Yes</b>	<b>Yes</b>
<b>PSI B1</b>	<b>IgG 1</b>	<b>GPIIIa (PSI domain)</b>	<b>h, m, p, rib</b>	<b>Yes</b>	<b>Yes</b>
<b>PSI C1</b>	<b>IgG 1</b>	<b>GPIIIa (PSI domain)</b>	<b>h, m, p, rib</b>	<b>Yes</b>	<b>Yes</b>
<b>PSI E1</b>	<b>IgG 2b</b>	<b>GPIIIa (PSI domain)</b>	<b>h, m, p, rib</b>	<b>Yes</b>	<b>Yes</b>
<b>HUTA A</b>	<b>IgG 2a</b>	<b>GPIIbIIIa</b>	<b>h</b>	<b>NA</b>	<b>Yes</b>
<b>HUTA B</b>	<b>IgG 1</b>	<b>GPIIbIIIa</b>	<b>h, m, p</b>	<b>No</b>	<b>Yes</b>

IgG, immunoglobulin G; mAb, monoclonal antibody; NA, not applicable.

mAbs were generated in GPIIbIIIa<sup>-/-</sup> and GPIIIa<sup>-/-</sup> mice. In addition to mouse (m), antibodies were also cross-reactive to other species, including tested human (h), pig (p), rat (r) and rabbit (rib). Antibodies cross-reactive with human antigens are in bold. ADP (20 μM)- or thrombin (1U)-induced human/mouse platelet aggregation was inhibited by most anti-GPIIbIIIa mAbs. Ristocetin (20 μg ml<sup>-1</sup>)/botrocetin (1.5 mg ml<sup>-1</sup>)-induced human/mouse platelet aggregation was inhibited by anti-GPIIbIIIa mAbs.




**Figure 1 | Anti-GPIIb/IIIa antibodies induce platelet activation.** Surface P-selectin expression on murine (**a,b**) or human platelets (**e,g,h**) and JON/A binding on murine (**c,d**) or PAC-1 binding on human platelets (**f**) were measured by flow cytometry following incubation with mAbs (**a,c,e,f,g**) or antisera (**b,d**). (**g**) FcγRIIIa/III blocker IV.3 was incubated with mAb 9D2 and platelets, and platelet P-selectin was assessed following. Only the healthy donor platelets that were significantly activated in the presence of 9D2 were tested;  $n = 3$ . (**h**) P-selectin expression was measured in healthy human platelets following incubation with anti-GPIIb/IIIa (ITP-1 to ITP-12) or anti-GPIIb/IIIa (ITP-a to ITP-l) antibody-positive ITP patient plasma. All flow cytometry data are expressed as fold change from nonspecific murine IgG (murine)- or IVIG (human)-treated control platelets (CTRL). Anti-GPIIb/IIIa mAbs shown as mean  $\pm$  s.e.m. of individual mAbs. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  versus CTRL as analysed by the Student's  $t$ -test (**a-f**) or one-way analysis of variance followed by Bonferroni *post hoc* analysis (**g,h**). NS, not significant.

GPIIb/IIIa and was susceptible to DANA inhibition (Fig. 2k). These data indicate that GPIIb/IIIa is likely the dominant target of anti-GPIIb/IIIa-mediated desialylation.

**Anti-GPIIb/IIIa antibodies induce surface expression of NEU1.** Since sialidase NEU1 has been reported to be involved in platelet

desialylation<sup>40</sup>, we established a method to detect surface platelet NEU1 using flow cytometry, and found that anti-GPIIb/IIIa, but not anti-GPIIb/IIIa or isotype control antibodies, induced NEU1 translocation onto both murine and human non-permeabilized platelets (Fig. 3a–f; Supplementary Fig. 4). This NEU1 was found to be abundant in the granules of permeabilized platelets (Fig. 3d). Consistent with our RCA-1-binding results (Fig. 2b,f),




**Figure 2 | Antibody-mediated platelet desialylation occurs mainly on the GPIIb/IIIa subunit.** Galactose exposure was detected with RCA-1 binding and measured by flow cytometry in murine (a–d) and human (e–j) platelets following incubation with mAbs (a,b,d,e,f–h,j,k) or antisera (c)  $n = 10$ –20. (d,g) Co-incubation with sialidase inhibitor DANA prior to addition of mAbs to murine (d) or human (g) platelets;  $n = 8$ . (h) Fc $\gamma$ RII/III blocker IV.3 was incubated with mAbs (9D2, M1 or HUTA B) and platelets, RCA-1 binding was assessed following. Only the healthy donor platelets that were significantly desialylated in the presence of these mAbs were tested;  $n = 4$ . (i) RCA-1 binding was measured in healthy human platelets following incubation with anti-GPIIb/IIIa (ITP-1 to ITP-12) or anti-GPIIb/IIIa (ITP-a to ITP-l) antibody-positive ITP patient plasma. (j) anti-GPIIb/IIIa-mediated RCA-1 binding was assessed following removal of GPIIb/IIIa with OSGE. (k) Representative western blot of RCA-1 binding (left), and probing with commercial anti-GPIIb/IIIa antibody (right) to confirm the identity of the RCA-1-positive band following incubation with anti-GPIIb/IIIa mAb (NIT F). RCA-1 binding on GPIIb/IIIa was also quantified by protein densitometry in the presence of DANA. All flow cytometry data are expressed as fold change from nonspecific murine IgG (murine)- or IVIG (human)-treated control platelets (CTRL). Anti-GPIIb/IIIa mAbs shown as mean  $\pm$  s.e.m. of individual mAbs. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  versus CTRL as analysed by the Student’s  $t$ -test (a–c,e,f) or one-way analysis of variance followed by Bonferroni *post hoc* (d,g–k). NS, not significant.

we observed a dose-dependent increase of NEU1 translocation with increasing concentrations of anti-GPIIb $\alpha$  mAb (Fig. 3c,f). Triple staining of P-selectin, RCA-1 and NEU1 on platelets following anti-GPIIb $\alpha$  mAb incubations revealed significant co-expression and correlation between these markers within the same platelet population ( $P < 0.001$  as assessed by Pearson's correlation, Supplementary Figs 5 and 6). These data not only strongly implicate NEU1 as the enzyme mediating desialylation, but also link desialylation with platelet activation.


**Platelet activation and desialylation positive feedback loop.** We next determined whether the observed anti-GPIIb $\alpha$  antibody effects were acting through canonical GPIIb $\alpha$  activation signalling cascades. We first tested whether various inhibitors of known downstream GPIIb $\alpha$  activation signalling molecules could

decrease anti-GPIIb $\alpha$  mAb-mediated platelet activation. We found inhibitors of intracellular  $Ca^{2+}$  flux (BAPTA-AM), P38MAPK activity (SB203580) and Src kinases (PP1) all significantly decreased anti-GPIIb $\alpha$  antibody-induced human platelet activation as measured by P-selectin, while Q-VD-OPh, a pan caspase inhibitor of platelet apoptosis did not appear to have any effect (Fig. 4a). Western blot analysis further demonstrated anti-GPIIb $\alpha$  mAb can directly mediate GPIIb $\alpha$  downstream signalling as evidenced by increased phosphorylation of p38MAPK (Fig. 4b), which could be inhibited by SB203580 and PP1 as quantified by densitometry (Fig. 4b,c). These data indicate that anti-GPIIb $\alpha$  antibodies directly mediate platelet activation through endogenous GPIIb $\alpha$  signalling pathways.

To further elucidate the link between anti-GPIIb $\alpha$ -mediated platelet activation and desialylation, we first tested whether inhibitors of platelet activation may affect platelet desialylation.



**Figure 3 | Anti-GPIIb $\alpha$  antibodies induce surface expression of NEU1.** Representative confocal images of surface expression of NEU1 on murine (a) and human (d) platelets stained with anti-NEU1 and anti-CD61 following incubations with anti-GPIIb $\alpha$  mAb (NIT G (murine), NIT B (human)) or anti-GPIIb $\alpha$  sera (murine). All other mAbs were also tested with similar results;  $n = 5-8$ . Total NEU1 was detected in permeabilized human platelets;  $n = 2$ . White scale bars, 5  $\mu$ M; yellow scale bars, 2  $\mu$ M. (b,c,e,f) Flow cytometric analysis of surface NEU1 expression on murine (b,c) and human (e,f) platelets following incubations with anti-GPIIb $\alpha$  mAb or sera. Anti-GPIIb $\alpha$  mAbs shown as mean  $\pm$  s.e.m. of individual mAbs;  $n = 5-8$ . All flow cytometry data are expressed as fold change from nonspecific murine IgG (murine)- or IVIG (human)-treated control platelets (CTRL). Anti-GPIIb $\alpha$  mAbs shown as mean  $\pm$  s.e.m. of individual mAbs. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  versus CTRL as analysed by the Student's  $t$ -test.



**Figure 4 | Anti-GPIIb platelet activation and desialylation is a positive feedback loop.** (a,d) Human platelets were pre-incubated with inhibitors of platelet activation including intracellular  $Ca^{2+}$  flux (BAPTA-AM), phosphorylation of P38MAPK (SB203580) and Src kinase (PP1) prior to addition of anti-GPIIb mAbs. Following which, platelet activation (P-selectin expression) (a) or desialylation (RCA-1 binding) (d) was detected via flow cytometry. # and ## indicate comparison with CTRL for a only;  $n=8$ . (b) Representative western blots of whole-platelet lysate following incubations with GPIIb mAbs with or without indicated inhibitors. Membranes were probed for phosphorylated p38MAPK (p-p38MAPK) then stripped and re-probed for total pMAP38K. (c) Densitometry protein quantification of p-P38MAPK detected in b. Data representative of three separate experiments. (e) Sialidase inhibitor DANA was added prior to anti-GPIIb mAb incubation. DANA-mediated inhibition of antibody-induced platelet activation was measured by P-selectin expression and detected via flow cytometry.  $n=6$ . (f) Schematic flow chart illustrating platelet activation-desialylation-positive feedback loop. Following initial anti-GPIIb antibody crosslinking of GPIIb subunits, activation signalling occurs leading to surface translocation of NEU1. NEU1 cleavage of terminal sialic residues on a GPIIb subunit facilitates receptor clustering, resulting in amplification of platelet activation. (g,h) NIT A, NIT B and NIT F Fab fragments were generated and their effects on platelet activation and desialylation on murine (g) and human platelets (h) were analysed by flow cytometry.  $n=5$ . All flow cytometry data are expressed as fold change from nonspecific murine IgG (murine)- or IVIG (human)-treated control platelets (CTRL), unless otherwise indicated. Anti-GPIIb mAbs shown as mean  $\pm$  s.e.m. of individual mAbs. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  as assessed by one-way analysis of variance followed by Bonferroni *post hoc* analysis. NS, not significant.

We found inhibitors of GPIIb/IIIa activation SB203580, BAPTA-AM and PP1, but not platelet apoptosis (Q-VD-OPh), markedly inhibited anti-GPIIb/IIIa mAb-induced desialylation (Fig. 4d). This indicates that GPIIb/IIIa activation is a prerequisite for anti-GPIIb/IIIa mAb-mediated desialylation. Conversely, to test whether desialylation had any effect on platelet activation, we treated platelets with the sialidase inhibitor DANA in the presence of anti-GPIIb/IIIa mAbs. DANA strongly inhibited anti-GPIIb/IIIa-induced P-selectin expression (Fig. 4e). Together, these data establish that, while GPIIb/IIIa activation may be required for desialylation, desialylation itself may further potentiate platelet activation. It has been previously reported that removal of bulky terminal sialic residues can facilitate GPIIb/IIIa-receptor clustering and outside-in signalling<sup>41,42</sup>. Thus, anti-GPIIb/IIIa antibody binding, which initiates platelet activation, NEU1 translocation and GPIIb/IIIa desialylation, creates a positive feedback loop culminating in additional P-selectin expression and platelet desialylation (Fig. 4f).

Since GPIIb/IIIa clustering has been linked to platelet signalling and activation<sup>43,44</sup>, we generated Fab monovalent antibody fragments from several anti-GPIIb/IIIa mAbs. Fab fragments incubated with both human and murine platelets did not cause significant platelet activation or desialylation (Fig. 4g,h). We thus propose that GPIIb/IIIa antibody crosslinking is fundamental for antibody-mediated platelet activation and desialylation.

**Platelet activation and desialylation occur *in vivo*.** To test whether our *in vitro* observations occur *in vivo*, anti-GPIIb/IIIa and anti-GPIIb/IIIa mAbs or antisera were injected into female BALB/c mice to induce thrombocytopenia. Platelets isolated from this model 16 h post injection were co-stained for anti-mouse IgG and RCA-1 or P-selectin to assess the percentage of anti-GPIIb/IIIa antibody-bound platelets that were positive for platelet activation and desialylation. We found that in NIT A-, NIT B- and NIT F-injected mice, >50% of antibody-bound platelets were desialylated, while NIT E-, NIT G- and NIT H-injected mice ranged from 20 to 40%. In addition, there was a significant proportion of antibody-bound platelets positive for P-selectin expression, albeit at lower percentages than desialylation (Fig. 5a,b). In contrast, platelets from thrombocytopenic mice injected with anti-GPIIb/IIIa mAb or antisera did not exhibit these effects (Fig. 5b). Overall, *in vivo* antibody-mediated platelet activation and desialylation were observed to be more pronounced than *in vitro*. Thus, anti-GPIIb/IIIa antibodies induced significant increases in platelet activation and desialylation in a clinically relevant model of ITP.

**Anti-GPIIb/IIIa-opsionized platelets can be cleared via the AMR.** The Ashwell–Morell receptor (AMR), an asialoglycoprotein counter receptor predominantly expressed on hepatocytes, was reported to mediate clearance of desialylated GPs<sup>45</sup>, and has been linked to maintenance of normal platelet turnover through the platelet deglycosylation state<sup>24,46</sup>. We suspected that the AMR may contribute to the destruction of the antibody-mediated desialylated platelets. To test this, we inhibited the AMR using asialofetuin and assessed the clearance of anti-GPIIb/IIIa-opsionized platelets. We found that following co-injection of anti-GPIIb/IIIa-opsionized platelets with asialofetuin, uptake of antibody-bound platelets through the AMR was attenuated, resulting in an increase by ~25% of circulating anti-GPIIb/IIIa-bound platelets compared with fetuin, a nonspecific control (Fig. 6a). Furthermore, asialofetuin did not rescue anti-GPIIb/IIIa mAb (9D2)- or antisera-opsionized platelets (Fig. 6b).

To further confirm the contribution of the AMR in Fc-independent anti-GPIIb/IIIa antibody-mediated thrombocytopenia, we first injected anti-GPIIb/IIIa mAbs into *FcγR*<sup>-/-</sup> mice and found thrombocytopenia still occurred (Fig. 6c), particularly when injected with anti-GPIIb/IIIa mAb NIT G (Supplementary Fig. 7a), while anti-GPIIb/IIIa mAbs failed to induce a significant decrease in platelets in these mice (Fig. 6d). We next compared the severity of thrombocytopenia between Ashwell–Morell-deficient (*Aspgr2*<sup>-/-</sup>) and syngeneic WT control mice and found thrombocytopenia in *Aspgr2*<sup>-/-</sup> mice was significantly attenuated when injected with the same concentration of anti-GPIIb/IIIa mAb (Fig. 6e; Supplementary Fig. 7b), suggesting that the AMR indeed plays a significant role in the clearance of anti-GPIIb/IIIa-bound platelets.

The importance of the AMR in clearance of anti-GPIIb/IIIa-opsionized platelets was further substantiated in macrophage-depleted mice. We found macrophage-depleted mice still maintained clearance of anti-GPIIb/IIIa-opsionized platelets from circulation, while clearance of anti-GPIIb/IIIa-opsionized platelets was almost completely rescued. In addition, co-injections of asialofetuin almost completely inhibited anti-GPIIb/IIIa-mediated platelet clearance (Fig. 7a). This suggests that the role of the AMR in anti-GPIIb/IIIa-antibody-mediated platelet clearance is dominant in the absence of macrophages.


Tissue sections of the spleen and liver revealed significant co-localization of anti-GPIIb/IIIa-opsionized platelets in the liver, but not in the spleen of macrophage-depleted mice, ( $P < 0.05$  as determined by the Student's *t*-test, Fig. 7c–e). Treatment with asialofetuin resulted in decreased platelet localization in the livers of macrophage-depleted mice (Fig. 7c). Although asialofetuin did not decrease platelet localization in WT livers, the fluorescent platelets do not appear to co-localize with AMRs (Fig. 7b), suggesting that they may be binding to other phagocytic cells (for example, Kupffer macrophages).

These findings indicate for the first time that the AMR on hepatocytes significantly contributes to the clearance of anti-GPIIb/IIIa mAb-opsionized platelets, particularly in the absence of macrophages. Thus, hepatocytes play a previously unappreciated and important role in platelet clearance in antibody-mediated thrombocytopenia.

**Sialidase inhibition can attenuate ITP.** Patients who test positive for anti-GPIIb/IIIa antibodies tend to be more refractory to standard first-line treatments, such as steroids and IVIG<sup>13,14,16</sup>. We explored the therapeutic potential of sialidase inhibitors in our murine ITP model. We found that pretreatment with DANA significantly decreased desialylation of platelets in anti-GPIIb/IIIa, but not anti-GPIIb/IIIa mAb-injected mice (Fig. 8a). Remarkably, DANA also rescued platelet counts in most of the anti-GPIIb/IIIa mAbs tested (NIT B, NIT E, NIT F, NIT G and NIT H) and anti-GPIIb/IIIa-sera-injected mice (Fig. 8b,c). As expected, DANA did not significantly increase platelet counts in anti-GPIIb/IIIa mAb- or sera-injected mice (Fig. 8c; Supplementary Fig. 8). We then tested the therapeutic potential of oseltamivir phosphate (Tamiflu), a commonly administered anti-influenza medication that inhibits viral neuraminidase, and found significant amelioration of platelet counts in our murine model of anti-GPIIb/IIIa-mediated ITP (Fig. 8d). In conclusion, this is the first study in mice to provide evidence to support utilization of sialidase inhibitors as a viable therapeutic alternative for refractory ITP patients.

## Discussion

We describe herein a novel FcγR-independent mechanism of platelet clearance in thrombocytopenia mediated predominantly by anti-GPIIb/IIIa antibodies, which is distinct from Fc-dependent




**Figure 5 | Anti-GPIIb/IIIa mAbs induce platelet activation and desialylation *in vivo*.** (a,b) ITP was induced by intraperitoneal injection of anti-GPIIb/IIIa mAbs (NIT A, NIT B, NIT E, NIT F, NIT G and NIT H) or sera. At 16 h post injection, platelets isolated from the mice were examined for activation (P-selectin) and desialylation (RCA-1) by flow cytometry; *n* = 3 per mAb. (a) Representative dot plots of isolated washed platelets from anti-GPIIb/IIIa mAb (NIT E)- and sera-injected mice double-stained for anti-mouse IgG (against anti-GPIIb/IIIa antibodies) (x axis) and RCA-1/P-selectin (y axis).

ITP in both mechanism and therapeutic management. We demonstrate both *in vitro* and *in vivo* that binding of mAbs to GPIIb/IIIa induced significant platelet activation, surface NEU1 translocation and platelet desialylation. Importantly, we found that ITP patient plasma containing anti-GPIIb/IIIa antibodies induced similar effects on healthy human platelets. This novel mechanism led to increased anti-GPIIb/IIIa-mediated platelet sequestration in the liver and involvement of the hepatocyte in the phagocytosis of platelets in ITP via a previously undescribed pathway. Most importantly, our data demonstrate that sialidase inhibitors can block this pathologic process and ameliorate thrombocytopenia. These findings not only reveal a new mechanism of ITP, but also introduce a potential new diagnostic tool (for example, RCA-1 and NEU1 staining) and a novel therapeutic method (for example, sialidase inhibition), which will have a particularly significant impact on patients refractory to current ITP therapies.

The Fc-independent platelet clearance observed in anti-GPIIb/IIIa-, but not anti-GPIIb/IIIa-mediated thrombocytopenia, is most likely due to the distinct effects the antibodies have on their

corresponding platelet receptors<sup>17,18</sup>. The ability of anti-GPIIb/IIIa antibodies to affect platelet signalling has been previously described. We previously observed in murine models of fetal/neonatal alloimmune thrombocytopenia that anti-GPIIb/IIIa antibodies increased both platelet activation and thrombus formation in the placenta resulting in miscarriage<sup>25</sup>. In addition, several studies have reported that anti-GPIIb/IIIa antibodies affect platelet function independent of the Fc region of IgG. Specifically, F(ab)<sub>2</sub> fragments of various anti-GPIIb/IIIa antibodies induced platelet agglutination and GPIIb/IIIa-dependent aggregation *in vitro*<sup>30,47</sup> and caused thrombocytopenia *in vivo* when tested as anti-thrombotic agents<sup>48,49</sup>. Here, we found that anti-GPIIb/IIIa antibodies induced platelet activation via an intracellular signalling cascade typical of von Willebrand factor binding. This led to the previously unobserved antibody-mediated desialylation of GPIIb/IIIa. In contrast, anti-GPIIb/IIIa antibodies did not induce these effects in murine platelets.


Interestingly, we found differences between murine and human platelet responses to anti-GPIIb/IIIa antibodies, whereby anti-GPIIb/IIIa mAbs and ITP patient plasma induced activation



**Figure 6 | Fc-independent anti-GPII $\alpha$ -mediated thrombocytopenia occurs via the AMR.** Mice were co-injected with (a) anti-GPII $\alpha$  (NIT G) or (b) anti-GPIIbIIIa mAb (9D2)- or polyclonal sera-opsonized CFMDA-labelled platelets with asialofetuin (AMR inhibitor) or fetuin (a nonspecific control). Mice were bled at indicated time points and the percentage of fluorescently labelled platelets remaining in circulation was assessed with flow cytometry;  $n=6$ . \* $P<0.05$  versus Fetuin-injected group at same time point as analysed by two-way analysis of variance followed by Bonferroni *post hoc* analysis. (c–e) Same doses of indicated mAb or anti-GPII $\alpha$  or anti-GPIIbIIIa mAbs (equal ratio mixture of individual antibody clones) were injected into age-matched  $Fc\gamma R^{-/-}$  (c,d) or  $Aspgr2^{-/-}$  (e) or WT control mice. Platelet counts were taken immediately prior to antibody injection (time 0) and 24 h later (time 24). (e) Data are represented as a percentage calculated from [(time 0 platelet count – time 24 platelet count)/time 0 platelet count]  $\times 100$ . \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.001$  as determined by the Student's *t*-test.

and desialylation of certain healthy donor platelets. We attributed this response to the low-affinity IgG receptor, Fc $\gamma$ RIIa (the only Fc $\gamma$ R expressed on human but not murine platelets), as IV.3 was shown to attenuate anti-GPIIbIIIa-mediated effects on human platelets. Therefore, it cannot be ruled out that some antibodies

targeting GPIIbIIIa may also lead to platelet activation and desialylation, particularly in severe cases of ITP where high antibody titres may be sufficient to induce immune-complex binding via platelet Fc $\gamma$ RIIa. Importantly, IV.3 had no significant effect on anti-GPII $\alpha$  antibody-mediated human platelet




**Figure 7 | Anti-GPIb $\alpha$  platelet clearance in macrophage-depleted mice is via the AMR.** (a–e) Macrophages were depleted with clondrate liposomes via intravenous injection prior to study, and CFMDA-labelled antisera-opsonized platelets were injected with asialofeuin or fetuin and circulating platelets were quantified (a) as described in Fig. 6.  $n = 5$ .  $^{\wedge}P < 0.01$  versus fetuin-injected group at the same time point.  $^*P < 0.05$ ,  $^{**}P < 0.01$  versus baseline as determined by two-way analysis of variance followed by Bonferroni *post hoc* analysis. (b–d) Tissue sections of the spleen and liver harvested from normal or macrophage-depleted mice following the above circulation studies and were stained with anti-ASPGR1/2 (liver; red) (b,c) or anti-F4/80 (spleen; red) (d). Nuclei were counterstained with 4',6-diamidino-2-phenylindole (blue). Arrows indicate co-localization of CFMDA-labelled platelets with ASPGR on hepatocytes. (e) Fluorescent platelet (green) localization was assessed with immunofluorescent microscopy at  $\times 60$  magnification and quantified with Image J. White scale bars, 10  $\mu$ M.  $^*P < 0.05$  as assessed by the Student's *t*-test. Data are representative of five randomly selected fluorescent images.

activation and desialylation, suggesting that anti-GPIb $\alpha$ -mediated platelet effects predominantly follow F(ab)<sub>2</sub> binding and are Fc independent. However, Fc $\gamma$ RIIa may exacerbate the anti-platelet effects and explain the stronger anti-GPIb $\alpha$ -mediated responses seen in human versus mouse platelets. Through its tyrosine-based activation motif, Fc $\gamma$ RIIa signalling has been previously shown to contribute to, and was correlated with antibody-mediated platelet activation<sup>31,50,51</sup>, particularly when associated with the GPIb complex<sup>31,51,52</sup>. This may also be a target mechanism for Fc $\gamma$ R-dependent therapies, such as IVIG, in both anti-GPIIbIIIa and anti-GPIb $\alpha$  ITP patients who are responsive to the therapy<sup>53</sup>.

We thus show that the anti-platelet effects of anti-GPIb $\alpha$  are fundamentally different from those of anti-GPIIbIIIa, whereby anti-GPIb $\alpha$  antibodies in ITP crosslink adjacent GPIb $\alpha$  subunits

causing GPIb $\alpha$ -receptor clustering and activation. While we found that desialylation is dependent on anti-GPIb $\alpha$ -induced platelet activation, we observed through sialidase inhibition assays that desialylation itself contributes to platelet activation. We propose that NEU1-mediated desialylation, through the removal of bulky sialic residues, facilitates further GPIb $\alpha$  clustering. As has been previously reported, GPIb complex clustering can induce platelet activation independent of GPIb agonist stimulation<sup>41,44</sup>. It is also conceivable that removal of bulky sialic residues may facilitate anti-GPIb $\alpha$ -antibody-mediated GPIb $\alpha$  crosslinking and signalling. These events synergize GPIb $\alpha$  signalling and platelet activation as demonstrated by increased P-selectin and NEU1 expressions. This indicates a positive feedback loop whereby platelet activation and NEU1-mediated



**Figure 8 | Sialidase inhibition rescues thrombocytopenia in a murine model of ITP. (a–c)** DANA or PBS was injected intraperitoneally immediately prior to anti-GPIb $\alpha$  or anti-GPIIbIIIa antibody injection (mAb or sera) to induce thrombocytopenia. **(a)** Platelets from antibody-injected mice were analysed for desialylation (RCA-1 binding) via flow cytometry. **(b)** Platelet numbers were enumerated and compared between DANA-treated or mock (PBS)-treated groups. **(c)** Cumulative platelet counts from all anti-GPIb $\alpha$  and anti-GPIIbIIIa antibody (9D2, M1, PSI C1 and antisera)-injected mice with or without DANA treatment. For individual platelet counts of anti-GPIIbIIIa-injected mice, please see Supplementary Fig. 7. **(d)** Oseltamivir phosphate was injected intravenously 2 h after anti-GPIb $\alpha$  mAbs injection (equal ratio mixture of individual mAb clones). Platelet enumeration was as described above. Data are shown as mean  $\pm$  s.e.m. platelet counts of individual mAbs. \* $P < 0.05$ , \*\*\* $P < 0.001$  as determined by the Student's *t*-test.

desialylation reinforce each other, synergistically contributing to platelet clearance. This positive feedback loop may explain why relatively low levels of autoantibodies in ITP patients can cause severe thrombocytopenia.

To date, the prevailing view has been that platelet clearance in ITP is mediated by Fc $\gamma$ Rs of reticuloendothelial system macrophages, primarily in the spleen<sup>2</sup>. Here, we provide the first evidence of a new phagocytic process involving the hepatocyte in mediating destruction of antibody-opsonized platelets. Platelet clearance via the AMR is dominant in the absence of macrophages, which may be analogous to ITP patients undergoing typical first-line treatments. As hepatic sequestration of platelets in ITP patients is correlated with refractoriness to splenectomy<sup>54,55</sup>, our findings that the hepatocyte AMR plays a

significant role in the clearance of anti-GPIb $\alpha$ -opsonized desialylated platelets provide a potential explanation for refractoriness to splenectomy, as well as to steroid and IVIG therapies.

The burden on hepatocytes in the clearance of antibody-bound desialylated platelets has never been studied. However, increased production of liver stress enzymes has been reported in untreated ITP patients<sup>56</sup>. Given that the liver is an important site for production of plasma coagulation factors required for hemostasis<sup>57</sup>, patients with anti-GPIb $\alpha$  antibodies may present with additional complications in the coagulation cascade and may experience a more severe bleeding phenotype. The liver is also the primary site for thrombopoietin production, thus there may be an indirect anti-GPIb $\alpha$  antibody effect on platelet production<sup>46</sup>.

Long-term increased hepatic clearance of platelets may affect the coagulation system or decrease platelet production in anti-GPIIb $\alpha$ -mediated ITP, and warrants further study.

We show in *Fc $\gamma$ R<sup>-/-</sup>* and *Aspgr2<sup>-/-</sup>* mice that anti-GPIIb $\alpha$  antibody-driven desialylation of platelet GPs significantly contributes to Fc-independent thrombocytopenia *in vivo*. This may explain findings in a recent report of a fatal case of refractory ITP where incubation of the patients' sera (positive for anti-GPIIb $\alpha$  antibodies only) with normal healthy human platelets caused significant platelet activation and desialylation<sup>58</sup>.

We found anti-GPIIb $\alpha$ -mediated platelet effects were susceptible to therapeutic intervention *in vivo*, as the sialidase inhibitors, DANA and oseltamivir, were able to rescue anti-GPIIb $\alpha$ -mediated thrombocytopenia in mice. Clinical relevance of this finding is supported by a recent study in a small cohort of patients, which found a greater platelet increase in oseltamivir-administered individuals independent of influenza infection<sup>59</sup>. This follows a case report of the successful treatment of an anti-GPIIb $\alpha$ -positive ITP patient with oseltamivir, who had been previously refractory to numerous first- and second-line therapies. Remarkably, on oseltamivir, he maintained a sustained platelet response<sup>60</sup>. It is possible that the therapeutic targets of oseltamivir in these patients may not only be limited to platelets, as sialidase inhibition may also target immune cells, contributing to the amelioration of thrombocytopenia through modulation of the immune response<sup>61,62</sup>. Conversely, NEU1 released from platelets may adversely target the same immune cells and amplify the anti-platelet response<sup>63</sup>. In addition, non-platelet-derived sialidases causing enhanced removal of desialylated platelets, as has been reported in various infectious diseases such as *Streptococcus pneumoniae*<sup>64</sup> and *Trypanosoma cruzi* (Chagas' disease)<sup>65</sup>, may provide links with infections and thrombocytopenia. This may also occur with influenza infection<sup>66</sup>, although direct evidence is lacking to date.

These findings also provide insights into the platelet activation–desialylation dialogue and its positive feedback loop, which may contribute to thrombosis and cardiovascular diseases. Platelet activation and desialylation have been previously described in coronary heart disease (CHD) patients<sup>67,68</sup>, in which the sialic content of platelets was inversely correlated with the severity of CHD<sup>67</sup>. In addition, compared with patients without CHD, CHD patients overall exhibited more desialylated platelets that were prone to aggregation with higher sensitivity to weak agonists, such as ADP and serotonin<sup>68,69</sup>. These reports strongly reinforce the notion that platelet desialylation potentiates activation of platelets in other disease states, which may result in aggregation and platelet consumption. Thus, this novel Fc-independent platelet clearance pathway may also be involved in the clearance of activated platelets or platelet microaggregates including embolized thrombi, and is likely relevant to other thrombocytopenias caused by antibodies, such as fetal/neonatal alloimmune thrombocytopenia, post-transfusion purpura and drug-induced thrombocytopenias.

In summary, we have demonstrated that anti-GPIIb $\alpha$  antibodies cause platelet activation and desialylation, two processes co-existing in a positive feedback loop. This leads to Fc-independent platelet clearance in the liver mediated by the AMR of the hepatocyte. Most importantly, this pathway is amenable to sialidase inhibition. Given that IVIG is extremely costly and a limited resource, and steroids are associated with severe side effects, these treatments should only be implemented to patients who will benefit. Patients with anti-GPIIb $\alpha$ -mediated ITP who present with significant platelet desialylation may be identified as likely non-responders to conventional first-line treatments and splenectomy. We should also not exclude the potential impact of sialidase inhibitor therapy on anti-GPIIbIIIa-mediated ITP, as

some anti-GPIIbIIIa antibodies may also cause platelet desialylation in human platelets. Clinical trials are required to test the diagnostic value of platelet desialylation and the therapeutic potential of sialidase inhibitors. Thus, our findings not only offer valuable implications for the diagnosis, prognosis and successful treatment of ITP, but also provide a potential mechanism in the clearance of activated platelets (emboli). As such, these findings may also have important implications in the field of alloimmune thrombocytopenias and cardiovascular diseases, although further investigation is required to test these hypotheses.

## Methods

**Mice.** *GPIIb $\alpha$ <sup>-/-</sup>* mice and *GPIIIa<sup>-/-</sup>* mice were originally described<sup>25</sup> and provided by Dr Zaverio M. Ruggeri and Dr Jerry Ware (The Scripps Research Institute) and Dr Richard O. Hynes (Massachusetts Institute of Technology), respectively. The mice were backcrossed to BALB/c (Charles River Laboratories) background 10 times, then bred to generate syngeneic gene-deficient mice. *Fc $\gamma$ R<sup>-/-</sup>* (C.129P2(B6)-*Fcer1g<sup>m1RAV</sup>N12*) (6–8 weeks) mice were purchased from Taconic. All aforementioned mice were housed in the St Michael's Hospital Research Vivarium, and all studies were approved by the St Michael's Hospital Animal Care Committee. Female mice between ages of 8 and 12 weeks were used for experiments. *Aspgr2<sup>-/-</sup>* mice and related experiments were performed by Dr. Karin Hoffmeister's laboratory at the Harvard Medical School.

**Monoclonal antibody generation.** *GPIIIa<sup>-/-</sup>* or *GPIIb $\alpha$ <sup>-/-</sup>* BALB/c female mice were transfused with 10<sup>8</sup> WT washed platelets per week, for 4–6 weeks. Immunized splenocytes were then fused with mouse myeloma cells Ag8.653, and hybridomas were selected by hypoxanthine–aminopterin–thymidine medium. Positive hybridomas were identified using flow cytometry and subcloned by limiting dilution. Antibody-secreting hybridomas were cultured in sera-free medium for large-scale antibody production. Monoclonal antibodies were purified using protein-G sepharose beads.

**Platelet aggregation assay.** Platelet aggregation was performed as previously described<sup>28,26,27,70</sup>. Platelet-rich plasma (PRP) was prepared from citrated whole blood (1:9 v/v) by centrifugation at 300g for 7 min. Gel-filtered platelets were purified from PRP using a Sepharose 2B chromatography column with PIPES buffer (5 mM PIPES, 137 mM NaCl, 4 mM KCl and 0.1% glucose, pH 7.0). Gel-filtered platelets or PRP (250  $\mu$ l, 2.5  $\times$  10<sup>8</sup> ml<sup>-1</sup>) were incubated with PBS, control IgG or anti-GPIIb $\alpha$  or anti-GPIIbIIIa mAbs for 10 min. To characterize anti-GPIIbIIIa antibodies, platelet aggregation was induced by 20  $\mu$ M ADP (for PRP) or 1 U ml<sup>-1</sup> thrombin (for gel-filtered platelets). As for anti-GPIIb $\alpha$  antibodies, platelet aggregation in PRP was induced by 20  $\mu$ g ml<sup>-1</sup> botrocetin (for mouse) or 1.5 mg ml<sup>-1</sup> ristocetin (for human) and monitored by a computerized Chrono-log aggregometer (Chrono-Log Corporation, Havertown, PA, USA).

**Patients.** The patient plasma samples utilized in the present manuscript were from our previous published study of 176 ITP patients conducted at the Anhui Medical University Hospital, Hefei, China<sup>16</sup>. Informed consent was obtained from all subjects and the study was approved by the Anhui Medical University research ethics committee. Plasma samples were characterized with MAIPA, and only those samples highly specific with either anti-GPIIb $\alpha$  with undetectable anti-GPIIbIIIa or anti-GPIIbIIIa with undetectable anti-GPIIb $\alpha$  were selected for studies in this manuscript. Twenty-four untreated ITP patients' plasma samples were included: 12 with anti-GPIIb $\alpha$  (patients ITP-1 to ITP-12) and 12 with anti-GPIIbIIIa (patients ITP-a to ITP-l) autoantibodies.

**Reagents and materials.** Inhibitors were used for the following: intracellular Ca<sup>2+</sup> increases: BAPTA-AM (EMD4 Biosciences), P38MAPK: SB203580 (Enzo Life Sciences), Src family protein tyrosine kinase: PPI (Sigma), neuraminidase: N-acetyl-2,3-dehydro-2-deoxy neuraminic acid sodium salt (DANA) (EMD4 Biosciences) and oseltamivir phosphate (Santa Cruz), pan-caspases: Q-VD-OPH (Sigma), cAMP: prostacyclin (PGI<sub>2</sub>) (Cayman) and AMR: asialofetuin and its control fetuin (Sigma). OSGE (Cedarlane) was used to clear GPIIb $\alpha$ .

**Blood collection and platelet isolation.** Procedures were approved by the Research Ethics Board of St Michael's Hospital (Toronto, ON, Canada) and conducted as previously described<sup>25,26,58</sup>. Venous blood was obtained from healthy volunteers by venipuncture into 3.2% trisodium citrate. PRP was prepared by centrifugation (10 min, 300g, no brake, 22 °C). Platelets were isolated from PRP and washed (15 min, 1,050g, no brake, 22 °C, with 10 ng ml<sup>-1</sup> PGI<sub>2</sub>) and resuspended in HEPES Tyrode's solution (145 mM NaCl, 5 mM KCl, 0.5 mM Na<sub>2</sub>HPO<sub>4</sub>, 1 mM MgSO<sub>4</sub>, 5 mM HEPES and 5 mM glucose, pH 7.2). Platelets were counted with a Z2 Series Coulter Counter (Beckman Coulter), adjusted to 200  $\times$  10<sup>6</sup> platelets per ml and stored at 22 °C for 30 min to regain responsiveness.

Sera were isolated from blood of healthy donors by high-speed centrifugation of the platelet-poor plasma and red blood cell fraction (5 min, 2,000g, 22 °C). For isolation of murine platelets, blood was collected from anesthetized mice in 100 µl of 130 mM trisodium citrate by retro-orbital eye bleed, and washed platelets were prepared as described above with human-washed platelets.

**In vitro platelet-antibody assays.** Platelets were treated with various mAbs (2.5 µg ml<sup>-1</sup>) or with sera from *GPIb*<sup>-/-</sup> or *GPIIIa*<sup>-/-</sup> mice that have been intravenously immunized 4 × weekly with 10<sup>8</sup> WT platelets<sup>25</sup>. Human platelets were also treated with sera from ITP patients (1/50 v/v) in HEPES Tyrode's solution, for 60 min at 22 °C. Unbound antibody was removed by centrifugation (15 min, 1,050g, no brake, 22 °C, with 10 ng ml<sup>-1</sup> PGI<sub>2</sub>). Platelets were resuspended in Tyrode's solution (pH 7.2) and incubated (30 min, 22 °C) to restore responsiveness before measurements. For visualization of antibody-mediated platelet aggregate formation, human or murine PRP were incubated with various mAb (2.5 µg ml<sup>-1</sup>) under stirring conditions (1,000 r.p.m.) for 10 min. The images of platelet aggregates were recorded using a digital camera (DP70; Olympus, Tokyo, Japan) under a Zeiss Axiovert 135 inverted fluorescent microscope (Zeiss, Oberkochen, Germany). In some experiments, various inhibitors were used, prior to addition of mAbs (15 min, 22 °C), P38MAPK inhibitor SB203580 (10 µM), Ca<sup>2+</sup> quencher BAPTA-AM (20 µM), Src family protein tyrosine kinase inhibitor PP1 (10 µM), Q-VD-OPH (50 µM), neuraminidase inhibitor DANA (1 mM) or FcγRIII/III inhibitor IV.3 (StemCell Technologies) (2.5 µg ml<sup>-1</sup>). In some experiments OSGE (80 µg ml<sup>-1</sup>) was used to remove the extracellular part of GPIIb following antibody incubation, as previously described<sup>43</sup>.

**Flow cytometry.** P-selectin expression was detected with FITC-labelled anti-P-selectin antibody (5 µg ml<sup>-1</sup>) (BD Biosciences) for murine platelets, or with PE-labelled (2 µg ml<sup>-1</sup>) (eBioscience) or Brilliant Violet 605 (0.5 µg ml<sup>-1</sup>) (Biolegend) anti-human CD62P (P-selectin) antibody for human platelets. GPIIb/IIIa activation was detected with JON/A-PE (5 µl per 10<sup>6</sup> platelets) (Emfret) or PAC-1-FITC (20 µl per test) (BD Biosciences) following platelet fixation in 1% paraformaldehyde for 15 min on murine and human platelets, respectively. To quantify glycosylation, platelets were incubated with fluorescein-labelled RCA-1 or fluorescein-labelled PNA or biotinylated Maackia Amurensis Lectin II or fluorescein-labelled Sambucus Nigra Lectin. All were purchased from Vector Laboratories and used at 0.5 µg ml<sup>-1</sup>, 15 min, 22 °C to measure exposure of sugar residues. Surface NEU1 expression was measured with rabbit anti-NEU1 antibody (clone H-300 Santa Cruz, 1:50 dilution) and detected with Alexa Fluor 647 secondary antibody (0.8 µg ml<sup>-1</sup>) (Molecular Probes/Invitrogen). Murine IgG binding was detected with Alexa Fluor 647 goat anti-mouse IgG (H + L) (0.8 µg ml<sup>-1</sup>) (Invitrogen) or. Fold increase is represented as percentage increase from gated control platelets set at 1% positive. A total of 10,000 platelet events were acquired and analysed on a MACSQuant (Miltenyi Biotec).

**Western blotting.** Human platelets were incubated with mAb (NIT A, NIT B or NIT F) and DANA or 10 µM PP1, or 10 µM SB253580 as described above and lysed in 1 × Laemmli buffer. For detection of phospho-p38MAPK, 1 × Halt protease inhibitor cocktail (Thermo Scientific) was also added. Samples were reduced with addition of 0.1 M dithiothreitol and boiled at 95 °C for 10 min. Platelet lysate was separated by SDS-polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membrane (GE Healthcare). For RCA-1 staining, membranes were probed with biotin-conjugated RCA-1 (2 µg ml<sup>-1</sup>) (Vector Labs) according to the manufacturer's instructions, mouse anti-human CD41b antibody (1:5,000) (clone EPR6995, Abcam) and with β-actin antibody (1:400) (clone C1, Santa Cruz). For phospho-p38MAPK, membranes were probed with phospho-p38MAPK (Thr180/Tyr182) antibody (1:5,000) (Cell Signaling Technology) at 4 °C overnight. Avidin conjugation to RCA-1 was performed with a Vectastain ABC kit (Vector Labs) according to the manufacturer's instructions. HRP-conjugated secondary anti-mouse antibody (1:5,000) (Santa Cruz) was then utilized. Blots were developed by ECL (Thermo Scientific) and visualized on the VersaDoc MP 4000 imaging system (Bio-Rad). Uncropped immunoblots are shown in Supplementary Fig. 9.

**Antibody fab generation.** NIT A, NIT B and NIT F Fab fragments were generated with Thermo Scientific IgG1 F(Ab)<sub>2</sub> and Fab preparation kits according to manufacturers' protocol. Briefly, 1 mg ml<sup>-1</sup> of antibody was desalted and digested with immobilized Ficin (beaded agarose resin) in the presence of 25 mM cysteine. Digest products were purified with Protein-G beads and dialysed and concentrated with Amicon Ultra-4 Centrifugal Filter Units (Millipore). Purified Fab was run on 10% SDS-polyacrylamide gel for visualization.

**Immunocytochemistry.** Platelets treated with anti-GPIIb or anti-GPIIb/IIIa antibodies as described above were fixed in 4% paraformaldehyde at 22 °C for 20 min and spun down onto poly-L-lysine-coated coverslips (BD Biosciences; 500g, 5 min). Cells were blocked overnight in PBS with 1% BSA at 4 °C. Cells were incubated with primary antibodies rabbit anti-NEU1 IgG (4 µg ml<sup>-1</sup>) (Santa Cruz) and our anti-CD61 mAb M1 (5 µg ml<sup>-1</sup>) overnight at 4 °C. The platelets were washed in

triplicate with PBS before addition of species appropriate secondary antibodies Alexa Fluor 488 and 647 (1:10,000) (Invitrogen). Images were taken with a Zeiss LSM 700 Confocal laser scanning microscope with a ×63 objective. Images were analysed with ZEN 2010 software (Zeiss) and Adobe Photoshop 7.

**In vivo platelet activation and desialylation.** The passive murine ITP model was used to induce thrombocytopenia<sup>12</sup>. Various anti-platelet mAbs were injected intraperitoneally. The amount of mAbs used was determined following titration to induce similar levels of thrombocytopenia. After titration, 0.75 µg of anti-GPIIb mAb (0.03 µg g<sup>-1</sup> total body weight) was found to be comparable to injection of 4 µg of anti-GPIIb/IIIa mAb (0.16 µg g<sup>-1</sup> total body weight). In some experiments, neuraminidase inhibitor DANA (2 mg or 0.08 mg g<sup>-1</sup> total body weight) was injected intraperitoneally 2 min prior to injection of mAbs. Alternatively, oseltamivir phosphate (0.25 mg or 0.01 mg g<sup>-1</sup> total body weight) was therapeutically intravenously injected 2 h after antibody injection. After 16 h, mice were bled via the saphenous vein, platelet count was measured with Coulter Z counter and PRP was analysed for P-selectin and RCA-1 binding via flow cytometry as described above.

**In vivo platelet clearance.** A total of 10<sup>8</sup> washed murine platelets were prepared as described above and labelled with 5 µM of CMFDA and incubated with anti-platelet mAbs (5 µg ml<sup>-1</sup>, 1 h, 22 °C), washed and injected intravenously into WT BALB/c mice. Platelet circulation was measured after transfusion of CMFDA-labelled platelets via enumeration of fluorescently labelled platelets in whole-blood samples after 1 (baseline), 15 and 30 min. To assess the contribution of AMRs on hepatocytes, a bolus injection of inhibitor asialofetuin (0.2 mg g<sup>-1</sup> total body weight) was administered via the tail vein and fetuin was used as control, as previously described<sup>24</sup>. At 10 min post transfusion, a booster injection of asialofetuin (0.1 mg g<sup>-1</sup> total body weight) was administered intraperitoneally. Some mice were depleted of their macrophages via intravenous injection of Clondate-encapsulated liposomes (0.01 ml g<sup>-1</sup> body weight) 48 h prior.

**Immunohistochemistry.** Following *in vivo* platelet clearance studies as described above, mice were anesthetized and drained of their blood via retro-orbital bleeding. Liver and spleen were harvested and snap-frozen in liquid nitrogen. Frozen tissue was sectioned (5 µm) with Leica Cryostat and fixed onto slides in ice-cold methanol. Slides were washed in 2% BSA and then incubated with primary rat anti-mouse F4/80 (1:1,000) (clone BM8, eBioscience) or rabbit anti-ASPGR1/1 (1:1,000) (Santa Cruz) overnight at 4 °C. Slides were then stained or anti-rat Cy3 or anti-rabbit Alexa Fluor 647 secondary antibody (1:5,000) for 2 h. Sections were mounted with Vectashield mounting medium containing 4',6-diamidino-2-phenylindole. Images were captured using Olympus upright fluorescence microscope and analysed with Adobe Photoshop 7 and Image J.

**Statistical analysis.** All data are presented as mean ± s.e.m. unless otherwise indicated. Statistically significant differences between controls were assessed by the Student's unpaired *t*-test (two tailed). Statistically significant differences between multiple groups were assessed by one-way or two-way analysis of variance with Bonferroni *post hoc* analysis, as indicated. Statistical analyses were performed using Prism software (GraphPad). A *P* value of 0.05 or less was considered significant.

## References

- Rodeghiero, F. *et al.* Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood* **113**, 2386–2393 (2009).
- McMillan, R. The pathogenesis of chronic immune thrombocytopenic purpura. *Semin. Hematol.* **44**, S3–S11 (2007).
- Cines, D. B., Bussel, J. B., Liebman, H. A. & Luning Prak, E. T. The ITP syndrome: pathogenic and clinical diversity. *Blood* **113**, 6511–6521 (2009).
- Mathias, S. D. *et al.* Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. *Health Qual. Life Outcomes* **6**, 13 (2008).
- Provan, D. *et al.* International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood* **115**, 168–186 (2010).
- Vianelli, N. *et al.* Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. *Haematologica* **90**, 72–77 (2005).
- Neunert, C. *et al.* The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood* **117**, 4190–4207 (2011).
- Harrington, W. J., Minnich, V., Hollingsworth, J. W. & Moore, C. V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. *J. Lab. Clin. Med.* **38**, 1–10 (1951).
- Beardsley, D. S. & Ertem, M. Platelet autoantibodies in immune thrombocytopenic purpura. *Transfus. Sci.* **19**, 237–244 (1998).

10. Bussel, J. B. Fc receptor blockade and immune thrombocytopenic purpura. *Semin. Hematol.* **37**, 261–266 (2000).
11. Nieswandt, B., Bergmeier, W., Rackebrandt, K., Gessner, J. E. & Zirngibl, H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. *Blood* **96**, 2520–2527 (2000).
12. Webster, M. L. *et al.* Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIb/IIIa versus GPIIb/IIIa antibodies. *Blood* **108**, 943–946 (2006).
13. Go, R. S., Johnston, K. L. & Bruden, K. C. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. *Haematologica* **92**, 283–284 (2007).
14. Peng, J. *et al.* Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. *J. Thromb. Haemost.* **12**, 497–504 (2014).
15. Chang, M. *et al.* Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis *in vitro*. *Blood* **102**, 887–895 (2003).
16. Zeng, Q. *et al.* Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIb/IIIa versus GPIIb/IIIa antibodies. *Am. J. Hematol.* **87**, 206–208 (2012).
17. Ozaki, Y., Asazuma, N., Suzuki-Inoue, K. & Berndt, M. C. Platelet GPIb-IX-V-dependent signaling. *J. Thromb. Haemost.* **3**, 1745–1751 (2005).
18. Shattil, S. J. & Newman, P. J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. *Blood* **104**, 1606–1615 (2004).
19. Du, X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. *Curr. Opin. Hematol.* **14**, 262–269 (2007).
20. Okumura, I., Lombart, C. & Jamieson, G. A. Platelet glycolalicin. II. Purification and characterization. *J. Biol. Chem.* **251**, 5950–5955 (1976).
21. Solum, N. O., Hagen, I., Filion-Myklebust, C. & Stabaek, T. Platelet glycolalicin. Its membrane association and solubilization in aqueous media. *Biochim. Biophys. Acta* **597**, 235–246 (1980).
22. Rumjantseva, V. *et al.* Dual roles for hepatic lectin receptors in the clearance of chilled platelets. *Nat. Med.* **15**, 1273–1280 (2009).
23. Wandall, H. H. *et al.* Galactosylation does not prevent the rapid clearance of long-term, 4 degrees C-stored platelets. *Blood* **111**, 3249–3256 (2008).
24. Sorensen, A. L. *et al.* Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. *Blood* **114**, 1645–1654 (2009).
25. Li, C. *et al.* The maternal immune response to fetal platelet GPIIb/IIIa causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. *J. Clin. Invest.* **121**, 4537–4547 (2011).
26. Lei, X. *et al.* Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation *in vitro* and *in vivo* in murine models of thrombosis. *Thromb. Haemost.* **111**, 279–289 (2014).
27. Yang, H. *et al.* Fibrinogen and von Willebrand factor-independent platelet aggregation *in vitro* and *in vivo*. *J. Thromb. Haemost.* **4**, 2230–2237 (2006).
28. Reheman, A. *et al.* Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. *Blood* **113**, 1809–1817 (2009).
29. Wang, Y. *et al.* Plasma fibronectin supports hemostasis and regulates thrombosis. *J. Clin. Invest.* **124**, 4281–4293 (2014).
30. Yanabu, M. *et al.* Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody. *Blood* **89**, 1590–1598 (1997).
31. Cauwenberghs, N. *et al.* Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor. *Thromb. Haemost.* **85**, 679–685 (2001).
32. Shattil, S. J., Hoxie, J. A., Cunningham, M. & Brass, L. F. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. *J. Biol. Chem.* **260**, 11107–11114 (1985).
33. Bergmeier, W. *et al.* Flow cytometric detection of activated mouse integrin alphaIIb beta3 with a novel monoclonal antibody. *Cytometry* **48**, 80–86 (2002).
34. King, M., McDermott, P. & Schreiber, A. D. Characterization of the Fc gamma receptor on human platelets. *Cell. Immunol.* **128**, 462–479 (1990).
35. Pfueller, S. L. & Luscher, E. F. The effects of aggregated immunoglobulins on human blood platelets in relation to their complement-fixing abilities. II. Structural requirements of the immunoglobulin. *J. Immunol.* **109**, 526–533 (1972).
36. Hoffmeister, K. M. *et al.* Glycosylation restores survival of chilled blood platelets. *Science* **301**, 1531–1534 (2003).
37. Zhang, Y. *et al.* Identification of selective inhibitors for human neuraminidase isoenzymes using C4,C7-modified 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) analogues. *J. Med. Chem.* **56**, 2948–2958 (2013).
38. Judson, P. A., Anstee, D. J. & Clamp, J. R. Isolation and characterization of the major oligosaccharide of human platelet membrane glycoprotein GPIb. *Biochem. J.* **205**, 81–90 (1982).
39. Kinlough-Rathbone, R. L., Perry, D. W., Rand, M. L. & Packham, M. A. Responses to aggregating agents after cleavage of GPIb of human platelets by the O-sialoglycoprotein endoprotease from *Pasteurella haemolytica*- potential surrogates for Bernard-Soulier platelets? *Thromb. Res.* **99**, 165–172 (2000).
40. Jansen, A. J. *et al.* Desialylation accelerates platelet clearance after refrigeration and initiates GPIIb/IIIa metalloproteinase-mediated cleavage in mice. *Blood* **119**, 1263–1273 (2012).
41. van der Wal, D. E. *et al.* Role of glycoprotein Iba mobility in platelet function. *Thromb. Haemost.* **103**, 1033–1043 (2010).
42. Gitz, E. *et al.* Improved platelet survival after cold storage by prevention of glycoprotein Iba clustering in lipid rafts. *Haematologica* **97**, 1873–1881 (2012).
43. van der Wal, D. E. *et al.* Platelet apoptosis by cold-induced glycoprotein Iba clustering. *J. Thromb. Haemost.* **8**, 2554–2562 (2010).
44. Kasirer-Friede, A. *et al.* Lateral clustering of platelet GP Ib-IX complexes leads to up-regulation of the adhesive function of integrin alpha IIb beta 3. *J. Biol. Chem.* **277**, 11949–11956 (2002).
45. Marshall, J. S. *et al.* Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. *J. Clin. Invest.* **54**, 555–562 (1974).
46. Grozovsky, R. *et al.* The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. *Nat. Med.* **21**, 47–54 (2015).
47. Alimardani, G., Guichard, J., Fichelson, S. & Cramer, E. M. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. *Thromb. Haemost.* **88**, 1039–1046 (2002).
48. Cadroy, Y. *et al.* Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. *Blood* **83**, 3218–3224 (1994).
49. Cauwenberghs, N. *et al.* Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. *Arterioscler. Thromb. Vasc. Biol.* **20**, 1347–1353 (2000).
50. Rubinstein, E., Kouns, W. C., Jennings, L. K., Boucheix, C. & Carroll, R. C. Interaction of two GPIIb/IIIa monoclonal antibodies with platelet Fc receptor (Fc gamma RII). *Br. J. Haematol.* **78**, 80–86 (1991).
51. Sullam, P. M. *et al.* Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor Fc gamma RIIA on the platelet plasma membrane. *J. Biol. Chem.* **273**, 5331–5336 (1998).
52. Shrimpton, C. N. *et al.* Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. *J. Exp. Med.* **196**, 1057–1066 (2002).
53. Urbanus, R. T. *et al.* Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Iba and Fc gamma RIIa in immune thrombocytopenia. *Haematologica* **98**, e70–e72 (2013).
54. Sarpatwari, A. *et al.* Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. *Br. J. Haematol.* **151**, 477–487 (2010).
55. Ghanima, W., Godeau, B., Cines, D. B. & Bussel, J. B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. *Blood* **120**, 960–969 (2012).
56. Enger, C. *et al.* Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). *Ann. Hepatol.* **10**, 188–195 (2011).
57. Davidson, C. J., Tuddenham, E. G. & McVey, J. H. 450 million years of hemostasis. *J. Thromb. Haemost.* **1**, 1487–1494 (2003).
58. Li, J. *et al.* Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. *Haematologica* **99**, e61–e63 (2014).
59. Jansen, A. J., Peng, J., Zhao, H. G., Hou, M. & Ni, H. Sialidase inhibition to increase platelet counts: a new treatment option for thrombocytopenia. *Am. J. Hematol.* **90**, E94–E95 (2015).
60. Shao, L. *et al.* Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. *Platelets* **26**, 495–497 (2014).
61. Nan, X., Carubelli, I. & Stamos, N. M. Sialidase expression in activated human T lymphocytes influences production of IFN-gamma. *J. Leukoc. Biol.* **81**, 284–296 (2007).
62. Chen, X. P., Enioutina, E. Y. & Daynes, R. A. The control of IL-4 gene expression in activated murine T lymphocytes: a novel role for neu-1 sialidase. *J. Immunol.* **158**, 3070–3080 (1997).
63. Seyrantepe, V. *et al.* Regulation of phagocytosis in macrophages by neuraminidase 1. *J. Biol. Chem.* **285**, 206–215 (2010).
64. Grewal, P. K. *et al.* The Ashwell receptor mitigates the lethal coagulopathy of sepsis. *Nature medicine* **14**, 648–655 (2008).
65. Tribulatti, M. V., Mucci, J., Van Rooijen, N., Leguizamon, M. S. & Campetella, O. The trans-sialidase from *Trypanosoma cruzi* induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents. *Infect. Immun.* **73**, 201–207 (2005).

66. Alioglu, B., Tasar, A., Ozen, C., Selver, B. & Dallar, Y. An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report. *Pathophysiol. Haemost. Thromb.* **37**, 55–58 (2010).
67. Mandic, R., Oppen, C., Krappé, J. & Wesemann, W. Platelet sialic acid as a potential pathogenic factor in coronary heart disease. *Thromb. Res.* **106**, 137–141 (2002).
68. Butun, I. I. *et al.* Preliminary study showing the relationship between platelet fibronectin, sialic acid, and ADP-induced aggregation levels in coronary heart disease. *Clin. Appl. Thromb. Hemost.* **13**, 308–312 (2007).
69. McGill, D. A. & Ardlie, N. G. Abnormal platelet reactivity in men with premature coronary heart disease. *Coron. Artery Dis.* **5**, 889–900 (1994).
70. Wang, Y. *et al.* Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. *J. Exp. Med.* **202**, 1587–1597 (2005).

### Acknowledgements

We are grateful to Dr Z. Ruggeri and Dr Jerry Ware, and Dr R. Hynes for providing the GPIIb $\alpha$ <sup>-/-</sup> and GPIIIa<sup>-/-</sup> mice, respectively. Alexandra H. Marshall provided valuable comments and contributed significantly to manuscript preparation. This work was supported by the Canadian Institutes of Health Research (MOP 97918, MOP 119540 and MOP 119551); Canadian Blood Services-Canadian Institutes of Health Research partnership fund (CIHR-BUC201403-HN-326400); Equipment Funds from the Canada Foundation for Innovation (Leaders Opportunity Fund: 31101), Canadian Blood Services and St Michael's Hospital. D.E.v.d.W., I.Y. and L.M. are recipients of the Canadian Blood Services Postdoctoral Fellowship. J.L. and B.V. are recipients of the Fellowship award from the Department of Laboratory Medicine and Pathobiology, University of Toronto.

### Author contributions

J.L. designed and performed the majority of experiments, analysed data and prepared the manuscript. D.E.v.d.W. designed and conducted experiments and analyzed data. G.Z. created the mAbs and provided guidance for study design and data interpretation. M.X., R.G., I.Y. and B.V. conducted some of the experiments. L.M. provided polyclonal sera. M.R., L.Z. and Q.Z. led the clinical study in Hefei and provided blood samples to the group in Toronto, Canada. V.L., K.M.H. and J.F. contributed to study design and interpretation, as well as manuscript preparation. As principle investigator, H.N. oversaw study design, data interpretation and manuscript preparation.

### Additional information

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission** information is available online at <http://npj.nature.com/reprintsandpermissions/>

**How to cite this article:** Li, J. *et al.* Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. *Nat. Commun.* **6**:7737 doi: 10.1038/ncomms8737 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>